Bahl & Gaynor Inc. grew its stake in GlaxoSmithKline PLC (NYSE:GSK) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,481 shares of the pharmaceutical company’s stock after purchasing an additional 150 shares during the period. Bahl & Gaynor Inc.’s holdings in GlaxoSmithKline PLC were worth $673,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GSK. FMR LLC grew its position in GlaxoSmithKline PLC by 11.7% in the 1st quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after purchasing an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans grew its position in GlaxoSmithKline PLC by 87,023.5% in the 1st quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after purchasing an additional 1,371,490 shares during the last quarter. Renaissance Technologies LLC grew its position in GlaxoSmithKline PLC by 42.7% in the 1st quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after purchasing an additional 1,316,600 shares during the last quarter. Bank of America Corp DE grew its position in GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the last quarter. Finally, Federated Investors Inc. PA grew its position in GlaxoSmithKline PLC by 22.7% in the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after purchasing an additional 833,501 shares during the last quarter. Institutional investors own 9.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/18/glaxosmithkline-plc-gsk-shares-bought-by-bahl-gaynor-inc.html.

Several analysts have issued reports on GSK shares. Argus restated a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a research report on Tuesday, July 18th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC (NYSE:GSK) opened at 40.24 on Monday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.53. The firm has a 50-day moving average of $39.80 and a 200-day moving average of $41.77. The firm has a market capitalization of $98.35 billion, a price-to-earnings ratio of 39.76 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The firm had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities research analysts forecast that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 4.88%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.